List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
In this article, Dr Lien Lybaert describes how the innate and adaptive immune system work together to produce an effective and durable antitumour response. She explains why the best strategy for personalised cancer therapy is therefore to identify major histocompatibility (MHC) binding epitopes to cover the full antigenic repertoire of…
In pre-clinical studies, a novel treatment decreased plaque formation, meaning it could be used to prevent Alzheimer's disease.
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
A new compound can inhibit the build-up of plaque in arteries and prevent atherosclerosis, researchers have shown.
Researchers have found that the S1/S2 cleavage of the SARS-CoV-2 Spike protein could be a potential target for COVID-19 therapeutics.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
High IFN signalling in pancreatic tumours are sensitive to NAMPT inhibitors which block a pathway in NAD synthesis, presenting a drug target.
A study has shown that targeting the protein Nsp1 can inhibit genes for viral replication, which could lead to new COVID-19 treatments.
A key process in β-cell regeneration has been discovered by researchers who say this could lead to improved treatments for diabetes.
Using NMR spectroscopy, researchers have partially observed the structure of heat shock proteins that bind to proteins that cause Huntington's disease.
A study has shown that inhibiting the enzyme PRMT5 can suppress the growth of glioblastoma cells in pre-clinical studies.